Patents by Inventor Laurent Bracco
Laurent Bracco has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8481701Abstract: The present invention concerns methods and compositions usable for diagnosing Alzheimer's disease in mammals, in particular humans. It particularly describes serum markers for Alzheimer's disease and their use in diagnostic methods. It also concerns tools and/or kits usable for implementing these methods (reagents, probes, primers, antibodies, chips, cells, etc.), their preparation and their use. The invention is usable to detect the presence or progression of Alzheimer's disease in mammals, including in the early phase, as well as for predicting the efficacy of an Alzheimer's disease treatment.Type: GrantFiled: March 30, 2009Date of Patent: July 9, 2013Assignee: Exonhit Therapeutics SAInventors: Anne-Charlotte Jarrige-Le Prado, Pascale Beurdeley, Diego Pallares, Fabien Rouet, Laurent Bracco
-
Patent number: 8003375Abstract: The invention concerns a method for identifying and/or cloning nucleic acid regions representing qualitative differences associated with alternative splicing events and/or with insertions, deletions located in RNA transcribed genome regions, between two physiological situations, comprising either hybridization of RNA derived from the test situation with cDNA's derived from the reference situation and/or reciprocally, or double-strand hybridization of cDNA derived from the test situation with cDNA's derived from the reference situation; and identifying and/or cloning nucleic acids representing qualitative differences. The invention also concerns compositions or banks of nucleic acids representing qualitative differences between two physiological situations, obtainable by the above method, and their use as probe, for identifying genes or molecules of interest, or still for example in methods of pharmacogenomics, and profiling of molecules relative to their therapeutic and/or toxic effects.Type: GrantFiled: November 19, 2009Date of Patent: August 23, 2011Assignee: ExonHit Therapeutics S.A.Inventors: Fabien Schweighoffer, Laurent Bracco, Bruno Tocque
-
Publication number: 20110086776Abstract: The present invention concerns methods and compositions usable for diagnosing Alzheimer's disease in mammals, in particular humans. It particularly describes serum markers for Alzheimer's disease and their use in diagnostic methods. It also concerns tools and/or kits usable for implementing these methods (reagents, probes, primers, antibodies, chips, cells, etc.), their preparation and their use. The invention is usable to detect the presence or progression of Alzheimer's disease in mammals, including in the early phase, as well as for predicting the efficacy of an Alzheimer's disease treatment.Type: ApplicationFiled: March 30, 2009Publication date: April 14, 2011Applicant: EXONHIT THERPEUTICS SAInventors: Anne-Charlotte Jarrige-Le Prado, Pascale Beurdeley, Diego Pallares, Fabien Rouet, Laurent Bracco
-
Publication number: 20100144555Abstract: The invention concerns a method for identifying and/or cloning nucleic acid regions representing qualitative differences associated with alternative splicing events and/or with insertions, deletions located in RNA transcribed genome regions, between two physiological situations, comprising either hybridization of RNA derived from the test situation with cDNA's derived from the reference situation and/or reciprocally, or double-strand hybridization of cDNA derived from the test situation with cDNA's derived from the reference situation; and identifying and/or cloning nucleic acids representing qualitative differences. The invention also concerns compositions or banks of nucleic acids representing qualitative differences between two physiological situations, obtainable by the above method, and their use as probe, for identifying genes or molecules of interest, or still for example in methods of pharmacogenomics, and profiling of molecules relative to their therapeutic and/or toxic effects.Type: ApplicationFiled: December 17, 2009Publication date: June 10, 2010Applicant: ExonHit TherapeuticsInventors: Bruno TOCQUE, Laurent Bracco, Florence Edon, Fabien Schweighoffer
-
Publication number: 20100144550Abstract: The invention concerns a method for identifying and/or cloning nucleic acid regions representing qualitative differences associated with alternative splicing events and/or with insertions, deletions located in RNA transcribed genome regions, between two physiological situations, comprising either hybridization of RNA derived from the test situation with cDNA's derived from the reference situation and/or reciprocally, or double-strand hybridization of cDNA derived from the test situation with cDNA's derived from the reference situation; and identifying and/or cloning nucleic acids representing qualitative differences. The invention also concerns compositions or banks of nucleic acids representing qualitative differences between two physiological situations, obtainable by the above method, and their use as probe, for identifying genes or molecules of interest, or still for example in methods of pharmacogenomics, and profiling of molecules relative to their therapeutic and/or toxic effects.Type: ApplicationFiled: November 19, 2009Publication date: June 10, 2010Applicant: Exonhit TherapeuticsInventors: Fabien Schweighoffer, Laurent Bracco, Bruno Tocque
-
Publication number: 20100055682Abstract: This application concerns methods and compositions that can be used for detecting the Alzheimer disease in mammals, particularly in humans. It describes in particular serum markers for Alzheimer's disease and the way they are used for diagnostic procedures. It also concerns tools and/or kits that can be used for applying these procedures (reagents, probes, primers, antibodies, chips, cells, etc.) with the preparation thereof and the way to use them. The invention can be used to detect the presence or the progression of Alzheimer illness in mammals, including at early stages of the disease.Type: ApplicationFiled: May 14, 2007Publication date: March 4, 2010Inventors: Fabien Schweighoffer, Laurent Bracco
-
Publication number: 20090298766Abstract: The present invention relates to methods and compositions for the detection and treatment of melanoma and skin cancers. More particularly, the invention discloses that BCSC-1 expression is altered in melanoma and skin cancer cells, allowing the design of effective detection methods and kits for such conditions. The invention also shows that restoring or increasing expression of BCSC-1 in melanoma and skin cancer cells suppresses tumorigenicity and represents a novel and effective approach for the treatment of melanoma and skin cancers. The invention may be used to detect the presence, stage or type of melanoma and skin cancers, as well as any predisposition thereto. The invention may be used in any mammalian subject, particularly human subjects.Type: ApplicationFiled: March 15, 2007Publication date: December 3, 2009Inventors: Vincent A. Piguet, Rafael Correa Rocha, Laurent Bracco
-
Publication number: 20090269744Abstract: The present application concerns methods and compositions which can be used to detect cancer in mammals, in particular in humans. It notably describes serum markers of cancers and their uses in diagnosis methods. It also concerns tools and/or kits which can be used to implement these methods (reagents, probes, primers, antibodies, chips, cells, etc.), their preparation and their uses. The invention can be used to detect the presence or the progression of a cancer, particularly breast cancer, including at an early stage.Type: ApplicationFiled: October 26, 2006Publication date: October 29, 2009Applicants: EXONHIT THERAPEUTICS SA, BIOMERIEUX SAInventors: Alexander Krause, Philippe Leissner, Malick Paye, Bruno Mougin, Fabien Schweighoffer, Laurent Bracco
-
Publication number: 20090264301Abstract: The present invention concerns new compositions and methods for the detection of pathological events. It more specifically concerns methods for the detection in vitro of the presence of a pathology or a pathological event in a subject, comprising taking a sample of blood cells from the subject and determining, in this sample, the presence of blood cells presenting a physiological state characteristic of the pathology. The invention also concerns the tools, kits and compositions for the implementation of such methods, as well as their uses in the field of human and animal health, or in experimental research for example.Type: ApplicationFiled: June 29, 2009Publication date: October 22, 2009Applicant: ExonHit Therapeutics SAInventors: Bruno Tocque, Laurent Bracco, Fabien Schweighoffer
-
Publication number: 20080254031Abstract: Genes and variant RNAs that are differentially expressed in human colon tumor tissues compared with normal colon tissue and the corresponding proteins are identified. These genes and the corresponding antigens are suitable targets for the treatment, diagnosis or prophylaxis of colon cancer.Type: ApplicationFiled: September 7, 2005Publication date: October 16, 2008Applicant: EXONHIT THERAPEUTICS SAInventors: Kevin McGowan, Vinayaka Kotraiah, Michael Brenner, Richard Einstein, Laurent Bracco
-
Patent number: 6933373Abstract: Proteins derived from the product of tumor suppressor gene p53 and having enhanced functions for therapeutical use are disclosed. The proteins advantageously have enhanced tumour suppressor and programmed cell death inducer functions, particularly in proliferative disease contexts where wild-type p53 protein is inactivated. Nucleic acids coding for such molecules, vectors containing same, and therapeutical use thereof, particularly in gene therapy, are also disclosed.Type: GrantFiled: October 3, 2001Date of Patent: August 23, 2005Assignee: Aventis Pharma S.A.Inventors: Emmanuel Conseiller, Laurent Bracco
-
Publication number: 20050112705Abstract: The present invention pertains to the field of biology, genetics and medicine. It particularly pertains to new methods for detecting, characterising and/or treating cancers, particularly prostate cancer. The invention also pertains to methods for identifying or screening for compounds that exhibit activity in these diseases. The invention also relates to the compounds, genes, cells, plasmids or compositions that can be used to carry out the methods herein above. The invention particularly describes the role in these diseases of variants of human kallikrein 2 and human kallikrein 3, also known by the name PSA, and their use as therapeutic, diagnostic or experimental targets.Type: ApplicationFiled: March 14, 2003Publication date: May 26, 2005Inventors: Laurent Bracco, Brigitta Brinkman, Fanny Coignard
-
Patent number: 6881571Abstract: The invention concerns a method for identifying and/or cloning nucleic acid regions representing qualitative differences associated with alternative splicing events and/or with insertions, deletions located in RNA transcribed genome regions, between two physiological situations, comprising either hybridization of RNA derived from the test situation with cDNA's derived from the reference situation and/or reciprocally, or double-strand hybridization of cDNA derived from the test situation with cDNA's derived from the reference situation; and identifying and/or cloning nucleic acids representing qualitative differences. The invention also concerns compositions or banks of nucleic acids representing qualitative differences between two physiological situations, obtainable by the above method, and their use as probe, for identifying genes or molecules of interest, or still for example in methods of pharmacogenomics, and profiling of molecules relative to their therapeutic and/or toxic effects.Type: GrantFiled: March 11, 1999Date of Patent: April 19, 2005Assignee: Exonhit Therapeutics S.A.Inventors: Fabien Schweighoffer, Laurent Bracco, Bruno Tocque
-
Patent number: 6852509Abstract: The invention concerns single-chain antibodies directed against the p53 protein, capable of being expressed in tumoral cells, capable of restoring a DNA binding in vitro and a transcription activator function in vivo. The invention also concerns nucleic acids coding for these molecules, the vectors containing them and their uses.Type: GrantFiled: October 27, 1997Date of Patent: February 8, 2005Inventors: Laurent Bracco, Laurent Debussche, Claude Caron De Fromentel
-
Publication number: 20040191828Abstract: The invention concerns a method for identifying and/or cloning nucleic acid regions representing qualitative differences associated with alternative splicing events and/or with insertions, deletions located in RNA transcribed genome regions, between two physiological situations, comprising either hybridization of RNA derived from the test situation with cDNA's derived from the reference situation and/or reciprocally, or double-strand hybridization of cDNA derived from the test situation with cDNA's derived from the reference situation; and identifying and/or cloning nucleic acids representing qualitative differences. The invention also concerns compositions or banks of nucleic acids representing qualitative differences between two physiological situations, obtainable by the above method, and their use as probe, for identifying genes or molecules of interest, or still for example in methods of pharmacogenomics, and profiling of molecules relative to their therapeutic and/or toxic effects.Type: ApplicationFiled: April 28, 2004Publication date: September 30, 2004Inventors: Fabien Schweighoffer, Laurent Bracco, Bruno Tocque
-
Publication number: 20030165931Abstract: The invention concerns a method for identifying and/or cloning nucleic acid regions representing qualitative differences associated with alternative splicing events and/or with insertions, deletions located in RNA transcribed genome regions, between two physiological situations, comprising either hybridization of RNA derived from the test situation with cDNA's derived from the reference situation and/or reciprocally, or double-strand hybridization of cDNA derived from the test situation with cDNA's derived from the reference situation; and identifying and/or cloning nucleic acids representing qualitative differences. The invention also concerns compositions or banks of nucleic acids representing qualitative differences between two physiological situations, obtainable by the above method, and their use as probe, for identifying genes or molecules of interest, or still for example in methods of pharmacogenomics, and profiling of molecules relative to their therapeutic and/or toxic effects.Type: ApplicationFiled: October 30, 2002Publication date: September 4, 2003Inventors: Bruno Tocque, Laurent Bracco, Florence Edon, Fabien Schweighoffer
-
Publication number: 20030059788Abstract: The present invention describes new methods for the determination of the potential toxicity of test compounds, as well as the kits and tools for the implementation of these methods. The invention also describes methods for generating nucleic acid sequences that can be used as genetic markers of toxicity. The invention is based in particular on the creation of differential nucleic acid banks characteristic of situations in which cell viability and/or proliferation are deregulated, and on the demonstration that these banks can be used to evaluate the toxicity profile of compounds with reliability and high sensitivity. The invention is of special utility in the pharmaceutical industry for analysis of the toxicity profile of compounds involved in drug development and/or in pharmaceutical compositions.Type: ApplicationFiled: August 2, 2002Publication date: March 27, 2003Inventors: Bruno Tocque, Laurent Bracco, Fabien Schweighoffer
-
Patent number: 6509153Abstract: The present invention describes new methods for the determination of the potential toxicity of test compounds, as well as the kits and tools for the implementation of these methods. The invention also describes methods for generating nucleic acid sequences that can be used as genetic markers of toxicity. The invention is based in particular on the creation of differential nucleic acid banks characteristic of situations in which cell viability and/or proliferation are deregulated, and on the demonstration that these banks can be used to evaluate the toxicity profile of compounds with reliability and high sensitivity. The invention is of special utility in the pharmaceutical industry for analysis of the toxicity profile of compounds involved in drug development and/or in pharmaceutical compositions.Type: GrantFiled: December 8, 1999Date of Patent: January 21, 2003Assignee: Exonhit Therapeutics SAInventors: Bruno Tocque, Laurent Bracco, Fabien Schweighoffer
-
Publication number: 20020193561Abstract: Proteins derived from the product of tumor suppressor gene p53 and having enhanced functions for therapeutical use are disclosed. The proteins advantageously have enhanced tumour suppressor and programmed cell death inducer functions, particularly in proliferative disease contexts where wild-type p53 protein is inactivated. Nucleic acids coding for such molecules, vectors containing same, and therapeutical use thereof, particularly in gene therapy, are also disclosed.Type: ApplicationFiled: October 3, 2001Publication date: December 19, 2002Applicant: Aventis Pharma S.A.Inventors: Emmanuel Conseiller, Laurent Bracco
-
Patent number: 6372432Abstract: The present invention concerns new compositions and methods for the detection of pathological events. It more specifically concerns methods for the detection in vitro of the presence of a pathology or a pathological event in a subject, comprising taking a sample of blood cells from the subject and determining, in this sample, the presence of blood cells presenting a physiological state characteristic of the pathology. The invention also concerns the tools, kits and compositions for the implementation of such methods, as well as their uses in the field of human and animal health, or in experimental research for example.Type: GrantFiled: December 8, 1999Date of Patent: April 16, 2002Assignee: Exonhit Therapeutics SAInventors: Bruno Tocque, Laurent Bracco, Fabien Schweighoffer